β-Amyloid1-42, HIV-1Ba-L (Clade B) infection and drugs of abuse induced degeneration in human neuronal cells and protective effects of ashwagandha (Withania somnifera) and its constituent Withanolide A

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Kurapati, Kesava Rao Venkata ^a   Samikkannu, Thangavel ^a   Atluri, Venkata Subba Rao ^a   Kaftanovskaya, Elena ^a   Yndart, Adriana ^a   Nair, Madhavan P N ^a  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN[1-42]; CHLOROFORM; COCAINE; FORMAZAN; METHAMPHETAMINE; METHANOL; MICROTUBULE ASSOCIATED PROTEIN 2; TRYPAN BLUE; UNCLASSIFIED DRUG; WITHANIA SOMNIFERA EXTRACT; WITHANOLIDE; WITHANOLIDE A; 3-RHAMNOPYRANOSYL(1-4)-GLUCOPYRANOSYL-12-DIACETOXY-20-HYDROXYWITHA-5,24-DIENOLIDE; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); NEUROPROTECTIVE AGENT; PEPTIDE FRAGMENT; STREET DRUG;

ARTICLE; CHEMOPROPHYLAXIS; COGNITIVE DEFECT; CONTROLLED STUDY; CYTOTOXICITY; DEGENERATIVE DISEASE; ENZYME ACTIVITY; ETHNOPHARMACOLOGY; EXOCYTOSIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 (STRAIN BA L); HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MTT ASSAY; NERVE CELL DEGENERATION; NEUROPATHOLOGY; NEUROPROTECTION; PROTEIN LOCALIZATION; WITHANIA SOMNIFERA; CELL LINE; CHEMISTRY; DRUG EFFECTS; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; NERVE CELL; PHYSIOLOGY; VIROLOGY; WITHANIA;

HUMAN IMMUNODEFICIENCY VIRUS 1; WITHANIA SOMNIFERA;

AMYLOID BETA-PEPTIDES; CELL LINE; HIV-1; HUMANS; NEURONS; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; STREET DRUGS; WITHANIA; WITHANOLIDES;

EID: 84912144696     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112818     Document Type: Article

References (60)

1. Williams P, Sorribas A, Howes MJ (2011) Natural products as a source of Alzheimer's drug leads. Natural Product Reports 28: 48-77.
2. Prabhulkar S, Piatyszek R, Cirrito JR, Wu Z, Li CZ (2012) Microbiosensor for Alzheimer's disease diagnostics: detection of amyloid beta biomarkers. J Neurochemistry 122: 374-381.
3. Zhang C, Tanzi RE (2012) Natural modulators of amyloid-beta precursor protein processing. Current Alzheimer Research 9: 1-8.
4. Hardy J (2006) A hundred years of Alzheimer's disease research. Neuron 52: 3-13.
5. Ross CA, Poirier MA (2004) Protein aggregation and neurodegenerative disease. Nature Medicine 10: S10-17.
6. Citron M (2004) Strategies for disease modification in Alzheimer's disease. Nature Reviews Neurosciences 5: 677-685.
7. Citron M (2010) Alzheimer's disease: Strategies for disease modification. Nature Reviews Drug Discovery 9: 387-398.
8. Iversen LL, Mortishire-Smith RJ, Pollack SJ, Shearman MS (1995) The toxicity in vitro of b-amyloid protein. Biochemical Journal 311: 1-16.
9. Bertram L, Lill CM, Tanzi RE (2010) The genetics of Alzheimer disease: back to the future. Neuron 68: 270-81.
10. Hardy JA, Higgins GA (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256: 184-185.
11. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356.
12. Tanzi RE, Bertram L (2005) Twenty years of the Alzheimer's disease hypothesis: a genetic perspective. Cell 120: 545-55.
13. Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, et al. (2013) Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 78: 1-13.
14. Green DA, Masliah E, Vinters HV, Beizai P, Moore DJ (2005) Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS 19: 407-411.
15. Esiri MM, Biddolph SC, Morris CS (1998) Prevalence of Alzheimer plaques in AIDS. Journal of Neurology Neurosurgery and Psychiatry 65: 29-33.
16. Soontomniyomkij V, Moore DJ, Soontomniyomkij B, Tatro ET, Umlauf A (2012) Cerebral b-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE e4 carriers. AIDS 26: 2327-35.
17. Giunta B, Ehrhart J, Obregon DF, Lam L, Le L (2011) Antiretroviral medications disrupt microglial phagocytosis of b-amyloid and increases its production by neurons: implications for HIV-associated neurocognitive disorders. Molecular Brain 4: 23-29.
18. Kulkarni SK, Dhir A (2008) Withania somnifera: An Indian ginseng. Progress in Neuropsychopharmacology and Biological Psychiatry 32: 1093-1105.
19. Mishra L, Singh BB, Dagenais S (2000) Scientific basis for the therapeutic use of Withania somnifera (Ashwagandha): a review. Alternative Medicine Review 5: 334-346.
20. Kuboyama T, Tohda C, KomatsuK (2005) Neurite regeneration and synaptic reconstruction induced by Withanolide A. British Journal of Pharmacology 144: 961-971.
21. Jain S, Shukla SD, Sharma K, Bhatnagar M (2001) Neuroprotective effects of Withania somnifera Dunn.in hippocampal sub-regions of female albino rat. Phytotherapy Research 15: 544-548.
22. Sankar SR, Manivasagam T, Krisnamurt A, Ramanathan M (2007) The neuroprotective effect of Withania somnifera root extract in MPTP-intoxicated mice: An analysis of behavioural and biochemical variables. Cell and Molecular Biology Letters 12: 473-481.
23. Sehgal N, Gupta A, Valli RK, Joshi SD, Mills JT, et al. (2012) Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc. Natl. Acad. Sci. USA 109: 3510-3515.
24. Kurapati VKR, Atluri VSR, Samikkannu T, Nair MPN (2013) Ashwagandha (Withania somnifera) Reverses b-Amyloid1-42 Induced Toxicity in Human Neuronal Cells: Implications in HIV-Associated Neurocognitive Disorders (HAND). PLOS ONE 8: e77624.
25. Wogulis M, Wright S, Cunningham D, Chilcote T, Powell K (2005) Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death. The Journal of Neuroscience 25: 1071-1080.
26. Pike CJ, Burdick D, Walencewicz A, Glabe CG, Cotman CW (1993) Neurodegeneration induced by b-Amyloid peptides in vitro: The role of peptide assembly state. The Journal of Neuroscience 13: 1676-1687.
27. Michaelis ML, Ansar S, Chen Y, Reiff ER, Seyb KI (2005) b-Amyloid-induced neurodegeneration and protection by structurally diverse microtubule-stabilizing agents. The Journal of Pharmacology and Experimental Therapeutics 312: 659-668.
28. Yankner BA, Duffy LK, Kirschner DA (1990) Neurotrophic and neurotoxic effects of amyloid b protein: reversal by tachykinin neuropeptides. Science 250: 279-282.
29. Kumar S, Seal CJ, Howes MJR, Kite GC, Okello EJ (2010) In vitro protective effects of Withania somnifera (L.) Dunal root extract against hydrogen peroxide and b-amyloid (1-42)-induced cytotoxicity in differentiated PC12 Cells. Phytotherapy Research 24: 1567-1574.
30. London JA, Biegel D, Pachter JS (1996) Neurocytopathic effects of b-amyloid-stimulated monocytes: A potential mechanism for central nervous system damage in Alzheimer disease. Proceedings of National Academy of Sciences USA 93: 4147-4152.
31. Isobe I, Michikawa M, Yanagisawa K (1999) Enhancement of MTT, a tetrazolium salt, exocytosis by amyloid b-protein and chloroquine in cultured rat astrocytes. Neuroscience Letters 266: 129-132.
32. Liu Y, Schubert D (1997) Cytotoxic amyloid peptides inhibit cellular 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide (MTT) reduction by enhancing MTT formazan exocytosis. Journal of Neurochemistry 69: 2285-2293.
33. Vinutha B, Prashanth D, Salma K, Sreeja SL, Pratiti D, et al. (2007) Screening of selected Indian medicinal plants for acetylcholinesterase inhibitory activity. Journal of Ethnopharmacology 109: 359-363.
34. Mohammad HS, Rita P, Ziqui S, Namrata S, Fabian C, et al. (2005) Microtubule-Associated Protein 2, a Marker of Neuronal Differentiation, Induces Mitotic Defects, Inhibits Growth of Melanoma Cells, and Predicts Metastatic Potential of Cutaneous Melanoma. American Journal of Pathology 166: 1841-1850.
35. Archana R, Namasivayan A (1999): Antistressor effect of Withania somnifera. Journal of Ethnopharmacology 64: 91-93.
36. Scartezzini P, Speroni E (2000) Review on some plants of Indian traditional medicine with antioxidant activity. Journal of Ethnopharmacology 71: 23-43.
37. Tohda C, Kuboyama T, Komatsu K (2000) Dendrite extension by methanol extract of Ashwagandha (roots of Withania somnifera) in SK-N-SH cells. NeuroReport 11: 1981-1985.
38. Zhao J, Nakamura N, Hattori M, Kuboyama T, Tohda C (2002) Withanolide derivatives from the roots of Withania somnifera and their neurite outgrowth activities. Chemical and Pharmaceutical Bulletin 50: 760-765.
39. Shearman MS, Ragan CI, Iversen LL (1994) Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of 1-amyloid-mediated cell death. Proc. Natl. Acad. Sci. USA 91: 1470-1474.
40. Koh J, Yang LL, Cotman CW (1990) b-Amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Research 533: 315-320.
41. Ohyagi Y, Asahara H, Chui DH, Tsuruta Y, Sakae N (2005) Intracellular Abeta42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease. FASEB Journal 19: 255-257.
42. Ohyagi Y, Tabira T (2006) Intracellular amyloid beta-protein and its associated molecules in the pathogenesis of Alzheimer's disease. Mini Reviews in Medicinal Chemistry 6: 1075-1080.
43. Ohyagi Y (2008) Intracellular amyloid beta-protein as a therapeutic target for treating Alzheimer's disease. Current Alzheimer Research 5: 555-561.
44. Melo JB, Agostinho P, Oliveira CR (2003) Involvement of oxidative stress in the enhancement of acetylcholinesterase activity induced by amyloid beta-peptide. Neuroscience Research 45: 117-127.
45. Esiri MM, Biddolph SC, Morris CS (1998) Prevalence of Alzheimer plaques in AIDS. J. Neurol. Neurosurgery Psychiatry 65: 29-33.
46. Green DA, Masliah E, Vinters HA, Beizai P, Moore DJ, et al. (2005) Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS 19: 407-411.
47. Rempel HC, Pulliam L (2005) HIV-1 Tat inhibits neprilysin and elevates amyloid beta. AIDS 19: 127-135.
48. Achim CL, Adame A, Dumaop W, Everall IP, Masliah E (2009) Increased accumulation of intraneuronal amyloid beta in HIV-infected patients. J. Neuroimmune Pharmacology 4: 190-199.
49. Xu J, Ikezu T (2009) The comorbidity of HIV-associated neurocognitive disorders and Alzheimer's disease: a foreseeable medical challenge in post-HAART era. J. Neuroimmune Pharmacology 4: 200-212.
50. Atluri VSR, Thangavel S, Kurapati VKR, Nair MPN (2014) Commentary of Drugs of Abuse and HIV Infection in South Florida, USA. Austin J Drug Abuse and Addiction 1: 1-3.
51. Kumar V (2006) Potential Medicinal Plants for CNS Disorders: an Overview. Phytotherapy Research 20: 1023-1035.
52. Hardy J, Selkoe DJ (2002) The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics. Science 297: 353-356.
53. Gatta LB, Albertini A, Ravid R, Finazzi D (2002) Levels of b-secretase BACE and a-secretase ADAM10 mRNAs in Alzheimer hippocampus. NeuroReport 13: 2031-2033.
54. Burdick D, Soreghan B, Kwon M, Kosmoski J, Knauer M, et al. (1992) Assembly and Aggregation Properties of Synthetic Alzheimer's A4/b Amyloid Peptide Analogs. Journal of Biological Chemistry 267: 546-554.
55. Patil S, Melrose J, Chan C (2007) Involvement of astroglial ceramide in palmitic acid-induced Alzheimer-like changes in primary neurons. European Journal of Neuroscience 26: 2131-2141.
56. Shirotani K, Tsubuki S, Iwata N, Takaki Y, Harigaya W (2001) Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan-and phosphoramidon-sensitive endopeptidases. Journal of Biological Chemistry 276: 21895-21901.
57. Eckman EA, Reed DK, Eckman CB (2001) Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme. Journal of Biological Chemistry 276: 24540-24548.
58. Hu JG, Igarashi A, Kamata M, Nakagawa H (2001) Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); Retards A beta aggregation, deposition, fibril formation, and inhibits cytotoxicity. Journal of Biological Chemistry 276: 47863-47868.
59. Van Nostrand WE, Porter M (1999) Plasmin cleavage of the amyloid beta-protein: Alteration of secondary structure and stimulation of tissue plasminogen activator activity. Biochemistry 38: 11570-11576.
60. Yan P, Hu XY, Song HW, Yin KJ, Bateman RJ (2006) Matrix metalloproteinase-9 degrades amyloidbeta fibrils in vitro and compact plaques in situ. Journal of Biological Chemistry 281: 24566-24574.